MODD vs. TLSI, LNSR, AVR, KRMD, LUNG, PDEX, ZJYL, PROF, CVRX, and LUCD
Should you be buying Modular Medical stock or one of its competitors? The main competitors of Modular Medical include TriSalus Life Sciences (TLSI), LENSAR (LNSR), Anteris Technologies Global (AVR), KORU Medical Systems (KRMD), Pulmonx (LUNG), Pro-Dex (PDEX), Jin Medical International (ZJYL), Profound Medical (PROF), CVRx (CVRX), and Lucid Diagnostics (LUCD). These companies are all part of the "medical equipment" industry.
Modular Medical vs.
TriSalus Life Sciences (NASDAQ:TLSI) and Modular Medical (NASDAQ:MODD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.
Modular Medical has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -206.24%. TriSalus Life Sciences' return on equity of 0.00% beat Modular Medical's return on equity.
In the previous week, TriSalus Life Sciences had 10 more articles in the media than Modular Medical. MarketBeat recorded 10 mentions for TriSalus Life Sciences and 0 mentions for Modular Medical. Modular Medical's average media sentiment score of 0.00 beat TriSalus Life Sciences' score of -0.21 indicating that Modular Medical is being referred to more favorably in the news media.
Modular Medical has lower revenue, but higher earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks.
TriSalus Life Sciences presently has a consensus price target of $10.93, indicating a potential upside of 104.27%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe TriSalus Life Sciences is more favorable than Modular Medical.
2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 27.5% of Modular Medical shares are held by institutional investors. 27.5% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 20.5% of Modular Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
TriSalus Life Sciences received 12 more outperform votes than Modular Medical when rated by MarketBeat users.
TriSalus Life Sciences has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Modular Medical has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
Summary
TriSalus Life Sciences beats Modular Medical on 10 of the 17 factors compared between the two stocks.
Get Modular Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MODD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Modular Medical Competitors List
Related Companies and Tools
This page (NASDAQ:MODD) was last updated on 5/23/2025 by MarketBeat.com Staff
